Cyprotex PLC Launch of in vitro service using 3D microtissues
April 14 2015 - 2:01AM
RNS Non-Regulatory
TIDMCRX
Cyprotex PLC
14 April 2015
Cyprotex PLC
("Cyprotex" or "the Company")
Cyprotex launches in vitro service using spontaneously beating
cardiac 3D microtissues
14(th) April, 2015; Cyprotex PLC (AIM:CRX), a specialist
ADME-Tox Contract Research Organisation (CRO), announced today the
launch of a new in vitro service to identify potential cardiotoxic
liabilities of pharmaceuticals. The service combines state of the
art 3D cell culture methods and confocal high content imaging
technology.
The 3D microtissues are formed from a co-culture of 3 different
types of cardiac cells present in the heart. Using this method, the
cells are able to beat spontaneously in a similar manner to a human
heart.
https://www.youtube.com/watch?v=6SchWIkb3Og
Confocal high content imaging technology uses fluorescent dyes
to stain particular regions of the cell to identify changes in
response to increasing doses of pharmaceutical drugs. Using this
technology, Cyprotex's research shows that the new 3D microtissue
model is able to accurately identify drugs which cause structural
damage to the heart. The service is complementary to our other
cardiotoxicity assays such as eCiphrCardio which evaluates changes
in electrical activity in the heart which may lead to cardiac
arrhythmia. By combining these techniques and using a more holistic
approach, Cyprotex are able to capture a wide range of cardiotoxic
liabilities using in vitro methods.
Dr Anthony Baxter, Cyprotex's Chief Executive Officer, comments:
'Drug induced cardiovascular toxicity is the leading cause of
attrition during drug development. Our expertise in the field of in
vitro toxicology has enabled us to develop a highly predictive and
sophisticated model for correctly identifying cardiotoxicity which
can be applied at an early stage of the drug development
process.'
Cyprotex recently presented this research at the Society of
Toxicology conference in San Diego in March 2015. More details of
the new service can be found on the Cyprotex website
http://www.cyprotex.com/3d-cardiac-microtissues
For further information:
Cyprotex PLC Tel: +44 (0) 1625
505 100
Dr Anthony Baxter, Chief Executive ir@cyprotex.com
Officer www.cyprotex.com
John Dootson, Chief Financial
Officer
Mark Warburton, Chief Operating
Officer and Legal Counsel
N+1 Singer (Nomad and broker to Tel: +44 (0)20 7496
Cyprotex) 3000
Shaun Dobson shaun.dobson@n1singer.com
Jen Boorer jennifer.boorer@n1singer.com
www.n1singer.com
Notes to Editors
About Cyprotex PLC
Cyprotex is listed on the AIM market of the London Stock
Exchange (CRX). It has sites at Macclesfield and Alderley Park,
both of which are near Manchester in the UK, and at Watertown, MA
and Kalamazoo, MI in the US. The Company was established in 1999
and works with more than 1000 partners within the pharmaceutical
and biotech industry, cosmetics and personal care industry and the
chemical industry. Cyprotex acquired Apredica and the assets of
Cellumen Inc. in August 2010 and the combined business provides
support for a wide range of experimental and computational ADME-Tox
and PK services. The acquisition of the assets and business of
CeeTox in January 2014 has enabled Cyprotex to expand its range of
services to target the personal care, cosmetics and chemical
industries. The Company's core capabilities include high quality in
vitro ADME screening services, mechanistic toxicology and high
content toxicology screening services, including our proprietary
CellCiphr(R) toxicity prediction technology, predictive modelling
using PBPK and QSAR techniques, including Cloe(R) PK for in vivo PK
prediction, and a range of skin, ocular and endocrine disruption
services. For more information, see www.cyprotex.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAIJMJTMBABBAA
Cyprotex (LSE:CRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cyprotex (LSE:CRX)
Historical Stock Chart
From Apr 2023 to Apr 2024
